← Eichor
Study identifier: NCT07180160 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Condition: Advanced Breast Cancer  ·  Sponsor: Wenjin Yin

PhasePhase 2
Planned participants123
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Wenjin Yin, M.D.  ·  86(21)68385569  ·  yinwenjin@renji.com

Always discuss trial participation with your own doctor first.

Locations (1)

Renji Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07180160